Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 5, 2009, Pages 362-366

  Sant'Anna, Flávia Marinho ^a   Velasque, Luciane ^a   Costa, Marli Jane ^a   Schmaltz, Carolina Arana ^a   Morgado, Mariza Gonçalves ^b   Lourenço, Maria Cristina ^a   Grinsztejn, Beatriz ^a   Rolla, Valéria Cavalcanti ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

AIDS; Effectiveness; HAART; Rifampicin; Tuberculosis

Indexed keywords

EFAVIRENZ; ETHAMBUTOL; INDINAVIR; INDINAVIR PLUS RITONAVIR; ISONIAZID; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR PLUS SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ADD ON THERAPY; ADULT; AIDS PATIENT; ARTICLE; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TUBERCULOSIS; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; EVALUATION; FOLLOW UP; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 77953692646     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000500010     Document Type: Article

References (18)

1. World Health Organization. Global tuberculosis control: Surveillence, planning, financing. World Health Organization Report 2008 [on the internet]. Geneva: WHO Press. Available at: http://www.who.int/tb/publications/global_report/2008.
2. Corbett E.L., Watt C.J., Walker N. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021.
3. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., et al. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect. 2005; 1-74.
4. Pozniak A.L., Miller R., Ormerod L.P. The treatment of tuberculosis in HIV-infected persons. AIDS. 1999;13:435-445.
5. Aaron L., Saadoun D., Calatroni I., et al. O. Tuberculosis in HIV- infected patients: a comprehensive review. Clin. Microbiol Infect. 2004; 10: 388-98.
6. Schmitt C, Riek M, Winters K, Schutz M et al. Unexpected hepatotoxicity of rifampicin and Saquinavir/Ritonavir in Healthy Male Volunteers. Arch Drug Info 2009;2:8-16
7. Pedral-Sampaio D.B., Alves C.R., Neto E.M., et al. Efficacy and Safety Efavirenz in HIV Patients on Rifampicin for Tuberculosis. Braz. J. Inf. Dis. 2004, 8:211-216.
8. Brasil, Ministério da Saúde. Guia de Tratamento: Recomendações para Terapia Anti-retroviral em Adultos e Adolescentes Infectados pelo HIV: 2008. Editora MS, Brasília. 2008. (disponível em www.aids.gov.br)
9. Collins K.R., Quinones-Mateu M.E., Toossi Z., et al. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev. 2002, 4:165-76.
10. Rolla V., Vieira M.A., Pinto D., et al. Safety efficacy and Pharmacokinetics of Ritonavir 400mg and saquinavir400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Invest. 2006;26(8):469-479.
11. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacocinetic interactions between Efavirenz and RIFAMPICIN in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;41:681-90.
12. Torres, T. S. and Rolla, V. C. What is the best strategy for treating TB-HIV co-infected patients with HAART and rifampicin without saquinavir? Int J Tuberc Lung Dis 2007;11(8):993-94
13. Saraceni V, King BS, Cavalcante SC, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2008 Jul; 12(7):769-72.
14. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360:119-29.
15. Campos DP, Ribeiro SR, Grinsztejn B, et al. Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003. Aids 2005,19 Suppl 4:S22-26.
16. Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS. 2008 Nov;3(6):653-9
17. Moreno S, Hernández B, Dronda F. Antiretroviral therapy in AIDS patients with tuberculosis AIDS Rev. 2006 Jul-Sep;8(3):115-24.
18. Karim SA, Naidoo KJ, Glober A, et al. Initiating ART during TB Treatment Significantly Increases Survival: Results of a Randomized Controlled Clinical Trial in TB/HIV-co-infected Patients in South Africa [abstract 36a]. In. Program and abstracts: 16th Conference on Retroviruses and Opportunistic Infections (Montreal) Canada 2009.